HealthQuill Clinical trials
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

Read More
GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.
Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.

Read More
The Food and Drug Administration has cleared the first at-home cervical cancer screening test in the US, according to a statement from Teal Health, its maker.
Health Medical Pharma

US approves first at-home cervical cancer screening from Teal Health

HQ Team May 12, 2025: The Food and Drug Administration has cleared the first at-home cervical cancer screening test in the US, according.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer therapy, nivolumab (Opdivo), offering a quicker administration option for eligible patients than the currently available drip treatment. 
Drugs Medical Pharma

UK regulator clears subcutaneous injection of Bristol Myers for cancers

HQ Team May 1, 2025: Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new under-the-skin injection version of the cancer.

Read More
Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the treatment of generalised myasthenia gravis (gMG) — a rare disease that causes muscle weakness and affects daily activities like chewing, swallowing, speaking, and breathing.
Drugs Health Pharma

US regulator approves Johnson & Johnson’s immune disorder drug

HQ Team April 30, 2025: Johnson & Johnson’s immune disorder drug has been approved by the US Food and Drug Administration for the.

Read More
British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal of the radiographic progression-free survival target in test patients.
Drugs Health Pharma

AstraZeneca stops prostate cancer trial, Q1 revenue up 10% to $13.6b

HQ Team April 29, 2025: British-Swedish pharmaceutical company AstraZeneca Plc. has discontinued its prostate cancer trial as it failed to meet the goal.

Read More
Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in the European Union of an oral drug for Duchenne muscular dystrophy in patients six years or older, who can walk.
Drugs Medical Pharma

Italfarmaco gets conditional marketing nod in EU for DMD drug

HQ Team April 27, 2025: Italfarmaco SpA., a privately held Italian pharmaceutical and chemical company, received a recommendation for the conditional marketing in.

Read More
Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms in patients who are already on regular medication.
Drugs Health Pharma

Bristol Myers’ oral medication for schizophrenia fails to meet main goal

HQ Team April 23: Bristol Myers Squibb’s investigational oral drug for treating schizophrenia in adults failed in its main goal to treat symptoms.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.
Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

Read More
Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in patients, two small trial studies show.
Drugs Health Research

Stem cell therapy revives hope for patients with Parkinson’s disease

HQ Team April 17, 2025: Stem cell therapies, which replace dead cells in the brain, can stop movement problems, rigidity and tremors in.

Read More